313 related articles for article (PubMed ID: 33921192)
41. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
[TBL] [Abstract][Full Text] [Related]
44. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
[TBL] [Abstract][Full Text] [Related]
45. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
46. Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGF
Du H; Gu J; Peng Q; Wang X; Liu L; Shu X; He Q; Tan Y
Oxid Med Cell Longev; 2021; 2021():2337818. PubMed ID: 34712379
[TBL] [Abstract][Full Text] [Related]
47. Research on the efficacy of Celastrus Orbiculatus in suppressing TGF-β1-induced epithelial-mesenchymal transition by inhibiting HSP27 and TNF-α-induced NF-κ B/Snail signaling pathway in human gastric adenocarcinoma.
Zhu Y; Liu Y; Qian Y; Dai X; Yang L; Chen J; Guo S; Hisamitsu T
BMC Complement Altern Med; 2014 Nov; 14():433. PubMed ID: 25370696
[TBL] [Abstract][Full Text] [Related]
48. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
Han D; Wu G; Chang C; Zhu F; Xiao Y; Li Q; Zhang T; Zhang L
Oncotarget; 2015 Dec; 6(38):40907-19. PubMed ID: 26517513
[TBL] [Abstract][Full Text] [Related]
49. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance.
Kim YJ; Choi WI; Jeon BN; Choi KC; Kim K; Kim TJ; Ham J; Jang HJ; Kang KS; Ko H
Toxicology; 2014 Aug; 322():23-33. PubMed ID: 24793912
[TBL] [Abstract][Full Text] [Related]
50. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
51. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
52. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
53. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
Arora R; Yates C; Gary BD; McClellan S; Tan M; Xi Y; Reed E; Piazza GA; Owen LB; Dean-Colomb W
PLoS One; 2014; 9(6):e98370. PubMed ID: 24896091
[TBL] [Abstract][Full Text] [Related]
54. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
55. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
56. Brucine suppresses breast cancer metastasis via inhibiting epithelial mesenchymal transition and matrix metalloproteinases expressions.
Li M; Li P; Zhang M; Ma F
Chin J Integr Med; 2018 Jan; 24(1):40-46. PubMed ID: 28795388
[TBL] [Abstract][Full Text] [Related]
57. Acacetin inhibits invasion, migration and TGF-β1-induced EMT of gastric cancer cells through the PI3K/Akt/Snail pathway.
Zhang G; Li Z; Dong J; Zhou W; Zhang Z; Que Z; Zhu X; Xu Y; Cao N; Zhao A
BMC Complement Med Ther; 2022 Jan; 22(1):10. PubMed ID: 35000605
[TBL] [Abstract][Full Text] [Related]
58. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition.
Niu W; Luo Y; Zhou Y; Li M; Wu C; Duan Y; Wang H; Fan S; Li Z; Xiong W; Li X; Li G; Ren C; Li H; Zhou M
J Exp Clin Cancer Res; 2020 Feb; 39(1):30. PubMed ID: 32028981
[TBL] [Abstract][Full Text] [Related]
59. Blocking TGF-β inhibits breast cancer cell invasiveness via ERK/S100A4 signal.
Wang XG; Meng Q; Qi FM; Yang QF
Eur Rev Med Pharmacol Sci; 2014; 18(24):3844-53. PubMed ID: 25555875
[TBL] [Abstract][Full Text] [Related]
60. Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells.
Zhang LL; Jiang XM; Huang MY; Feng ZL; Chen X; Wang Y; Li H; Li A; Lin LG; Lu JJ
Phytomedicine; 2019 Jan; 52():32-39. PubMed ID: 30599910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]